作者
Chinonyerem O Iheanacho, Valentine U Odili, Uchenna IH Eze
发表日期
2021/12
来源
Future Journal of Pharmaceutical Sciences
卷号
7
页码范围
1-10
出版商
Springer Berlin Heidelberg
简介
Background
Angiotensin-converting-enzyme-2, being the receptor for SARS-CoV-2, is increased in the use of RAAS inhibitors. Therefore, concerns have been raised over risks of SARS-CoV-2 infection and poor prognosis of COVID-19 in persons with prior exposure to these drugs. This study aimed to systematically review available evidence for associations between exposure to RAAS inhibitors with susceptibility to SARS-CoV-2 infection and clinical outcomes in infected persons. It hopes to address the question on the effects of RAAS inhibitors on the risk of COVID-19 and its prognosis.
Main body
Search was conducted in the databases of PubMed, Scopus, Cochrane, Embase and MedRxiv.org from December 2019 to May 31, 2020, using relevant keywords. Additional articles were identified through hand-searching of …
学术搜索中的文章
CO Iheanacho, VU Odili, UIH Eze - Future Journal of Pharmaceutical Sciences, 2021